Compass Therapeutics

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. immuno-oncology product candidates include a clinical-stage monoclonal antibody targeting solid tumors, a novel bispecific targeting PD-1 and PD-L1, and a portfolio of bispecific and monoclonal antibodies at various stages of pre-clinical development. The company was founded by Thomas J. Schuetz on March 20, 2018 and is headquartered in Boston, MA.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.

BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced poster presentations on CTX-009, the Company's bispecific DLL4/VEGF-A antibody, at the Cholangiocarcinoma Foundation (CCF) 2024 Annual Conference to be held at the Salt Palace Convention Center in Salt Lake City, Utah from April 17–19, 2024.

Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference

BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the Stifel Targeted Oncology Days taking place virtually April 16 – 17, 2024.

Compass Therapeutics to Participate in the Stifel Targeted Oncology Days

BOSTON, April 09, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today presents a poster on the combination of its bispecific antibody, CTX-009, and its agonistic anti-CD137 antibody, CTX-471, on anti-tumor activity in preclinical models at the 2024 American Association for Cancer Research (AACR) Annual Meeting taking place at the San Diego Convention Center in San Diego, California on April 9.

Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Lithium Americas Corp

SoundHound AI Inc

Today we will be looking at three penny stocks with the power to 10x your $1K investment. The three firms discussed below have outsized potential to turn a small capital allocation into a much larger return.

3 Penny Stocks With the Power to 10X Your $1K Investment

Enrollment in COMPANION-002, the Phase 2/3 randomized study of CTX-009 (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC), continues to progress well; top-line data from this study are expected by the end of 2024. Enrollment in COMPANION-003, the Phase 2 study of CTX-009 in patients with advanced colorectal cancer (CRC) was completed in the first quarter of 2024; top-line data from Stage 1 of this study are expected by mid-year 2024.

Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update

BOSTON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the Leerink Partners Global Biopharma Conference in Miami Beach, Florida on Wednesday, March 13, 2024.

Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

Compass Therapeutics, Inc. (CMPX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: Here's What You Should Know

BOSTON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported a business update.

Compass Therapeutics Provides Corporate Update

The heavy selling pressure might have exhausted for Compass Therapeutics, Inc. (CMPX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Compass Therapeutics, Inc. (CMPX) Loses -28.57% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported third quarter and year-to-date, 2023 financial results.

Compass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

AstraZeneca

Intuitive Surgical

During the pandemic era, several healthcare stocks skyrocketed. The focus was, however, on biopharma companies with an early-mover advantage related to the vaccine against Covid-19.

3 Healthcare Stocks To Make You The Millionaire Next Door: October Edition

BOSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of September 2023.

Compass Therapeutics to Participate in Upcoming Investor Events

BOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported second quarter, and year-to-date, 2023 financial results.

Compass Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

BOSTON, June 22, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that it will be added to the Russell 2000 ® and Russell 3000 ® Indexes as part of the Russell indexes annual reconstitution, effective after the US market opens on June 26, 2023.

Compass Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexes

BOSTON, May 04, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported first quarter 2023 financial results.

Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update

BOSTON, April 19, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the Stifel 2023 Virtual Targeted Oncology Days, which is taking place on April 25 – 26, 2023.

Compass Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days

BOSTON, March 28, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the Cantor Fitzgerald Future of Oncology Symposium, which is taking place virtually on April 3 – 5, 2023.

Compass Therapeutics to Participate in the Cantor Fitzgerald Future of Oncology Symposium

BOSTON, March 15, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported fourth quarter and full year 2022 financial results.

Compass Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

BOSTON, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the SVB Securities Global Biopharma Conference, which is taking place virtually on February 13 – 16, 2023.

Compass Therapeutics to Participate in the SVB Securities Global Biopharma Conference

Compass to Host Investor Event on Monday, January 23rd at 8:30am ET

Compass Therapeutics Announces that the Phase 2 Data of CTX-009 in Combination with Paclitaxel in Patients with Biliary Tract Cancers (BTC) will be Presented at the ASCO GI Cancers Symposium on January 20, 2023

BOSTON, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”; Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the first patient has been dosed in the Phase 2 U.S. study of CTX-009 in patients with metastatic colorectal cancer who are being treated in the third- and fourth-line setting.

Compass Therapeutics Announces First Patient Dosed in the Phase 2 U.S. Study of CTX-009 in Patients with Metastatic Colorectal Cancer

BOSTON, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that updated results from the ongoing Phase 2 study of CTX-009 combined with paclitaxel in patients with biliary tract cancer (BTC) will be presented at a poster session of the 2023 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) taking place in San Francisco, CA January 19-21, 2023. Additional poster presentations by Compass include trials in progress posters for the ongoing Phase 2/3 study of CTX-009 combined with paclitaxel in patients with biliary tract cancers (BTC) and the ongoing Phase 2 study of CTX-009 in patients with metastatic colorectal cancer (CRC).

Compass Therapeutics Announces Presentation of Updated Results from the Ongoing Phase 2 study of CTX-009 in Biliary Tract Cancer (BTC) at the 2023 ASCO GI Cancers Symposium January 19-21

BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”; Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the first patient has been dosed in the Phase 1b study of CTX-471 in combination with KEYTRUDA®, Merck's anti-PD-1 therapy, in patients with advanced solid tumors.

Compass Therapeutics Announces First Patient Dosed in the Phase 1b CTX-471 Combination Trial with KEYTRUDA® (pembrolizumab)

BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that the Company will participate in the Piper Sandler 34th Annual Healthcare Conference, which is taking place at the Lotte New York Palace November 29 – December 1, 2022.

Compass Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference

BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported third quarter and year-to-date 2022 financial results and provided a corporate update.

News for Compass Therapeutics Stock (CMPX)